Shots: The approval is based on P-III PARAGON-HF study involves assessing of Entresto (sacubitril/valsartan) in the treatment of patients with preserved ejection fraction HFpEF The expanded indication enables potential treatment […]readmore
Tags : Chronic Heart Failure
Shots: The approval is based on P-III DAPA-HF trial involves assessing of Forxiga (10mg, qd) + SOC (ACEi or ARB) vs PBO + SOC in 4,744 patients with HFrEF (LVEF […]readmore
Shots: The approval is based on pivotal P-III VICTORIA trial involves assessing of Verquvo (2.5mg, 5mg & 10mg) vs PBO in 5,050 adult patients with symptomatic CHF and LVEF less […]readmore
Shots: The NDA submission was submitted to NMPA’s CDE and is based on P-III VICTORIA study, seeking regulatory approval of vericiguat in China In Oct’2014, Bayer and MSD signed a […]readmore
Shots: The two P-III EMPERIAL-preserved & -reduced studies involve assessing the effect of 12wks. treatment of Jardiance (qd, 10mg) vs PBO in 315 & 312 patients with CHF along with […]readmore
Shots: The Fast Track designation follows two P-III EMPEROR-Reduced & EMPEROR-Preserved studies assessing Empagliflozin (qd) vs PBO in 8,500+ patients with heart failure with reduced & preserved ejection fraction, both […]readmore
Shots: The approval is based on P-III SHIFT study trial assessing Corlanor vs PBO +SoC in 6500+ patients with reduced left ventricular function (LVEF ≤35%) and heart rate ≥70 bpm, […]readmore